Era7 Bioinformatics

MainImage

599,474.20€

Out of 600,000.00€

investors

62

Est. ROI

500%

days left

--

The Microbiome is reshaping human health, agrifood and environment fields. Invest in Era7 Bioinformatics to participate in this revolution.

Finish date: 31/12/2016 Granada

Premoney valuation

2,400,000.00€

Percentage offered

20.00%

Est. ROI

500%

Exit horizon

2020

The project

 

This crowfunding campaign is a unique opportunity to co-invest with a Venture Capital in Era7 Bioinformatics, a company focused on the revolution of the Microbiome and new solutions to address the problem of antibiotic resistance.

Era7 Bioinformatics uses its own algorithms and cloud software to analyze billions of bacterial DNA sequences to extract from bacterial genomic and metagenomic Big Data findings and discoveries relevant for many fields as Medicine and Human Health, Agriculture, Biotechnology, Biofuels or Environment.

The objective of this round is to fund an expansion plan to grow especially in the United States and to optimize the integration and automation of our advanced software tools in the cloud that allow us to efficiently cope with the large increase in sales that is expected. Era7 Bioinformatics is a company with an exceptional team with experience, with clients in Europe and the United States and with a proven business model on the market. This expansion plan is aimed at a market that is growing exponentially and, in addition our target is every researcher working on Microbiome and also any end user in any of the Microbiome fields of application.

In this round we count with a Venture Capital specialized in Life Sciences that validates the quality of the project and demonstrates confidence in the growth prospects of Era7 Bioinformatics.

Business opportunity

Era7 Bioinformatics: The revolution of the Microbiome

The genomics revolution has changed Biology and Medicine. Genomics generates continuously massive data that it is needed to analyze using bioinformatics methods to translate it in comprehensible and ready to interpretation data useful for researchers and clinicians.

Bacteria are all over the world: in the air, in the soil, in the plants, in all living organisms. Bacteria are definitively important in Medicine, Veterinary, Agriculture, Environmental sciences,  alternative energies field, agrifood,…

We are assisting to a new revolution of the genomics: the Microbiome revolution. The Microbiome is the set of bacteria that live in an organism, in an environmental niche (a lake, a beach, a crop), in a place (your home, a hospital, your mobile phone). To know the Microbiome is very important for health, on one hand for fighting against pathogen bacteria and on the other hand to promote  the beneficial bacteria that maintain a healthy balance in our tissues.

ERa7 participates in the National Microbiome Initiative

Human microbiome encodes 300-fold more genes than the genes encoded by the human genome. We have more than 1000 different types of microorganisms in our microbiome.

Microbiome is related with cancer, with obesity, with allergies, and even with some Central Nervous System diseases as autism or with mood states. The interest of the Microbiome as biomarker for many diseases is certainly not discussable. 

In addition many products of great interest in biotechnology are being extracted from marine microbiomes or extreme environments as the Antarctica or some volcanoes. From these peculiar microbiomes can be extracted enzymes for industrial use, antibiotics, antitumoral drugs, new medications or enzymes for biodiesel production.

The application areas for the Microbiome are multiple: human health, new treatments of diseases, as biomarker, in infections, to discover new drugs for cancer treatment, antibiotics production, food, agriculture, environment, veterinary and many others since all space, all living organism, and all object has a specific microbiome that can be actionable. 

Microbiome application areas

 

International Big projects, as the Human Microbiome project or the Earth Microbiome Project, centered on the characterization of the microbiome of the human body and of the Earth, respectively, show the immense interest that Microbiome brings forward all over the world. This interest is also palpable in the high number of publications about Microbiome that is growing each year:

Pubmed papers about Microbiome

https://figshare.com/articles/Pubmed_Papers_on_Microbiome_vs_Year/2059782

Key processes as the antibiotic resistance, considered by CDC as a serious threat for public health, can be addressed with new solutions thought the light of the microbiome knowledge, since the resistant bacteria arise not isolated, but in the community of microorganisms that compose a microbiome. It seems clear that some multi-resistant highly pathogenic strains appear in wastewater plants or in industrial farms due to the continued antibiotic treatment of the animals to get a faster growth. Thus, to study the antibiotic resistant bacteria in the microbiome of the water depuration plant of a city, or in the microbiome of a hospital, or in the microbiome of a farm for milk production can help to solve the problem of the antibiotic resistance in a more global way, solving the actual root of the problem.

Recently it has been discovered the importance of the Microbiome in the treatment of diseases caused by bacteria. One example is the case of Clostridium difficile infections, frequently with fatal outcome, in which, using fecal microbiome transplant, total recovery without antibiotic treatment has been reported. New possible treatments of bacterial infections based on actionable microbiome elements could avoid the appearance of new antibiotic resistances.

Bacterial Genomics and Microbiome BIG DATA

The study and characterization of the Microbiomes is being possible due to the appearance of the new sequencing technologies that are able to generate massive sequence data (BIG DATA) with a significatively lower cost. In the table we can see that the quantity of genomic data expected for 2025 (1 zettabyte of bases/year and until 40 Exabytes per year of storage) are, in many aspects, higher than the data managed in Astronomy, in YouTube o en Twitter.

BIG DATA figures in Bacterial Genomics

Gigabyte (GB)

1.000.000.000

Terabyte (TB)

1.000.000.000.000

Petabyte (PB)

1.000.000.000.000.000

Exabyte (EB)

1.000.000.000.000.000.000

Zettabyte

1.000.000.000.000.000.000.000

This massive sequencing raw data is not interpretable or useful without the needed analytical processing. It is needed a complex analysis to translate this raw data in comprehensible, intelligible and interpretable results. This crucial transformation from BIG DATA to specialized knowledge requires to be focused in a specific knowledge area. This allows understanding and responding the questions that scientists and clinicians need to respond when they try to use the genomics in their daily activity. This is the reason why Era7 is focused in a specific area: the bacteria.

The bacterial genomics data represents an important percentage of the genomics data and the Microbiome revolution will probably result in a very high rate of growth of them.

These are the current estimates about the quantity of sequences in February 2016 for the different kingdoms (data from microbiomes are not included)

  • Human and animal sequences: 62.267.687 sequences
  • Plant sequences: 33.036.414 sequences
  • Bacterial sequences: 23.450.438 sequences

The revolution of the Microbiome that we are witnessing has changed the dimensions of the problem since, now, we need to analyze not one bacterial genome but all the genomes of a diverse and immense population of bacteria. This makes the analysis and the interpretation more complex.

It is probable that very soon each patient has his/her genome done, and, even sooner, that each patient has several Microbiome studies from gut, skin and blood in his/her Electronic Health Record. The genome data is constant and only suffers changes depending on the appearance of new manners of analyzing or interpret genome sequence data. On the contrary, the Microbiome is in a continuous change. We can consider it as a complex biomarker that is needed to check to know its response to different conditions as for example to compare healthy and disease conditions, before and after a treatment states or in different feed or stress conditions. All this carries us to expect that a high percentage of the BIG DATA from Genomics will come from Microbiome studies.

Era7 is ready for the challenge of the Microbiome

Era7 is ready to face this Microbiome challenge because we know how to work with BIG DATA, we have a wide experience in Genomics and massive sequencing technologies and we are expert in bacterial genomics and know how to translate massive data into findings with practical impact. One proof of that was the selection by Google of our project Bio4j (www.bio4j.com) for the program Google Summer of Code 2014 (http://bio4j.com/blog/2014/10/bio4j-goes-to-gsoc-mentor-summit-2014/). Companies and organizations from all the fields applied to this program, some of them very famous as Twitter, Apache or Mozilla.

Era7 Bio4j selected for the Google Summer of Code 2014

Bio4j is a graph database, developed by Era7 that includes:

  • More than 2000 millions of relationships
  • More than 500 millions of nodes
  • More than 1000 millions of attributes

Bio4j integrates all data from genes, proteins, their function and the relationships between them, from all the organisms, extracted from the most important databases: Uniprot, Gene Ontology, Genebank, NCBI taxonomy, EnzymeDB,…). The different types of elements included in Bio4j are represented in the following figure.

Interpretation of Genomics BIG DATA

A crucial element in the massive data interpretation is the visualization of data. Era7 provides new ways of interactive visualizations to facilitate the interpretation of results. See here an example of interactive visualization that we provide:

http://s3-eu-west-1.amazonaws.com/era7p/patho/data/out/parallel-coordinates/examples/gene-location.html

In many projects we have got transform the massive data (BIG DATA) into valuable findings for the researcher and into results understandable and expressive for the clinician. It has been possible due to our multidisciplinary team, absolutely needed to develop studies for this new type of genomic experiments. We have a team with experts in bacterial genomics, in cloud computing and in BIG DATA. It includes clinicians, lab people, biochemists, computer scientist, mathematicians, programmers and bioinformaticians. And the most important and peculiar thing, in Era7 team all the people talk the same language because the mathematicians know about biology, the biochemists do programming tasks and the medical doctors do bioinformatics algorithms and modeling of graph databases.

Investment & Exit

Reasons to invest in Era7 Bioinformatics

  • Because Era7 has already a trained multidisciplinary team of mathematicians, bioinformaticians, medical doctors, biochemists integrated with a software development team, a team specifically prepared for doing this project. Thus, Era7 has the potential for a quick growth with the possibility of getting strong rates of return.
  • Because the expected growth for the Genomics Big Data market is impressive. It is expected to have a 1 zetta bases per year of storage needs (1.000.000.000.000.000.000.000 bases per year) and a big percentage of this data will come from the Microbiome. A proof of that is an important Initiative that Obama administration has recently launched: the National Microbiome Initiative (NMI). Era7 is already participating in this important initiative about the Microbiome and lived at the white house the event of the launching of this initiative:

  • Because the barrier to entry for competitors is the need to have a complex knowledge very difficult to acquire because is highly specialized, cutting edge and requires multidisciplinary expertise. Era7 has already that specialized multidisciplinary knowledge and the know how. It is easy to buy a sequencing machine but it is not possible to build a multidisciplinary team in a while. This needs years of advanced and specialized formation in this specific field.
  • Because Era7 is already doing projects in EEUU and already selling in EEUU. The proof of concept is already done
  • Because Era7 has already a network of relationships in EEUU. We have worked with important pharma companies, with Hospitals, with Universities and with first-level biotech companies.
  • Because start-ups fight for a place in Boston’s biotech hub (http://www.nature.com/news/start-ups-fight-for-a-place-in-boston-s-biotech-hub-1.17721) and Era7 is already in this biotech hub, at Kendall Square in the CiC. The best hospitals (Massachusetts General Hospital, Dana Farber, Boston Children Hospital, etc.) the best Universities (Harvard, MIT, Tufts, etc.) the best research facilities of pharma and biotech companies (AstraZeneca, Pfizer, Novartis, Biogen Idec, Genzyme, etc.) are there in a biotech hub in which the innovative scientific and technical activity is frenetic.

Kendall Square, a densely populated neighbourhood in Cambridge and the heart of Boston’s booming biotechnology industry. “You can’t walk two feet there without seeing someone in biotech,” he says. “That kinetic energy of having everybody squished together — it leads to a lot of advantages you can’t get outside the city.”

Kevin Bitterman

  • Because the core of the Era7 products/services is already developed and tested in the market. The level of satisfaction of our clients is very high and we only need to improve the automation of the processes and to reinforce our presence in EEUU for scaling the sales. These are the main goals of the carefully designed expansion plan to be funded by this investment round

 

 

 

Drivers

The team of Era7 is multidisciplinary covering bioinformatics, mathematics, software development, biochemistry, microbiology, immunology, biotechnology and medicine. A team formed by people with different backgrounds is able to analyze the same problem from different point of views. Era7 Bioinformatics team is a really enthusiastic and experienced team, passionate about Genomics, Big Data and New NGS technologies. Difficult projects are a challenge for us and an opportunity for designing and developing new solutions.

Dr. Eduardo Pareja and Dr. Raquel Tobes are the founders of Era7 Bioinformatics. 

 

Eduardo Pareja, CEO

Eduardo Pareja, CEO

Eduardo Pareja is a Medicine Doctor that began working in transplant Immunology and did his PhD Thesis about human HLA-DR antigens in 1981 while working as a professor of Biochemistry at The University of Córdoba (Spain). After that, he went to work at a regional hospital as Head of the Section of Immunology where he run a Transplant Immunology Unit and very soon he pioneered in Spain the application of Molecular Biology to clinical immunological environments. At the same time he worked in Bioinformatics and Theoretical Biology developing programs for tissue typing and genomic typing. In this period he published different papers in International Journals, he directed several PhD Thesis and designed innovative genomic typing methods for HLA-DR genes.

During his last period of work at the hospital he was in charge of the Web Applications area in The Medical Informatics Department.
In 2005 he left the Hospital to found, with Raquel Tobes, Era7 Bioinformatics (www.era7bioinformatics.com).  Working as the CEO of Era7, Eduardo Pareja has built a multidisciplinary team and led the company to a position in which Era7 Bioinformatics is the leader in Spain in Next Generation Sequencing for Bacterial Genomics and Metagenomics and it is a company ready to internationalize due to its portfolio of Cloud Computing based Bioinformatics solutions and to the International relationships that Eduardo Pareja has helped to build.

ResearchGate Profile

LinkedIn Profile:

Twitter account:


 

Raquel Tobes, CSO

Raquel Tobes, CSO

PhD thesis about new algorithms for pattern searching in biological sequences based in finite state machines.

She has worked in research at the Hospital Virgen de las Nieves and at CSIC where she supervised several students.
From 2004 she is Research Director of Era7 Bioinformatics where she also is a co-founder.

Her main expertise is about Genomics, Next Generation Sequencing, Bioinformatics, Biological Databases, Bacterial Genomics and Metagenomics, Comparative genomics for bacterial pathogens, DNA repetitive sequences and Genomics Plasticity. In these fields she is mainly interested in the design and development of new algorithms, models, pipelines and visualizations to help in the interpretation of knowledge data related with sequences.

ResearchGate Profile:

LinkedIn Profile:

Twitter account:


 

Marina Manrique, COO

Marina Manrique, COO

MSc Biochemistry. MSc in Mathematical Biology. Bioinformatician with ample experience in Next Generation Sequencing (NGS) and Bacterial Genomics. She has special interest in bacterial metabolic pathways and she was deeply involved in the first annotation of the bacterial genome of the Escherichia coli EHEC Germany outbreak. 

She is also very active in the developing and evolution of the Era7 bioinformatics bacterial genome annotation system BG7 and in the development of new bioinformatics pipelines of data analysis.

ResearchGate Profile:

LinkedIn Profile:

Twitter account:


 

Eduardo Pareja-Tobes, CTO

Eduardo Pareja-Tobes, CTO

Mathematician. He leads the bioinformatics software development and cloud computing department.

He has developed an intense research activity working in algorithm design and in the design and development of cloud-based architectures. He is an expert in cloud, parallelization, graph databases and advanced programming languages as Scala. His research interests are algorithms for sequence analysis and category theory in systems biology. He is now very interested in new mathematical approaches for new algorithms dealing with assembly of data from Next Generation Sequencing.

He is leading open source research projects in this area at Era7 Bioinformatics.

ResearchGate Profile:

LinkedIn Profile:

Twitter account:


 

Alexey Alekhin, Software developer

Alexey Alekhin, Software developer

Mathematician. He is graduated from the Saint Petersburg State University with a degree in Mathematics.

He participated as Early Stage Researcher in the INTERCROSSING International Training Network, at Era7 Bioinformatics. After that period of training he continued working at Era7 collaborating in the development of the Research open source projects of Era7 Bioinformatics.
He is doing his Doctoral Thesis applying concepts from category theory to bioinformatics.

ResearchGate profile:

LinkedIn profile:


 

Alexis Lucena, software developer specialist in Web applications

Alexis Lucena, software developer specialist in Web applications

Alexis Lucena has more than 10 years' experience as software developer at Era7. He is specialist in web applications and has led projects of web application development for hospitals and biotech companies. He leads the open source project Doplanning, an Era7 web application for collaborative work between teams.

He has experience programming  Java, ColdFusion, ActionScript, HTML, Javascript, MySQL, PostggreSQL, Oracle, Informix, XML and using Cloud Computing (Amazon Web Services).

He is a key person in the development of frienly user interfaces for Era7's bioinformatics tools.

Linkedin profile:


 

Pablo Pareja-Tobes, project leader

Pablo Pareja-Tobes, project leader

Java developer. He is an expert in graph based databases.

He has been talking about Bio4j in many places and forums and he has been working as a visiting scientist in the Center for Applied Plant Science at the Ohio State University extending and integrationg Bio4j for plant genomics and transcriptomics.

He is also very interested in graphic representation of Big Data and new programming languages like Scala.

ResearchGate Profile:

LinkedIn Profile:

Twitter account:

Partners & Associates

 

The National Microbiome Initiative

The National Microbiome Initiative

Era7 participa en la National Microbiome Initiative cuyo lanzamiento tuvo lugar el 13 de Mayo de 2016 en la Casa Blanca. Eduardo Pareja asistió al evento de lanzamiento de la iniciativa. 

La NMI tiene como objetivo el avance del conocimiento sobre el comportamiento del microbioma y sobre la forma de proteger y restaurar la función de un microbioma saludable. Los 3 principales áreas de trabajo de eesta iniciativa son:

  • La investigación interdisciplinar para contestar la preguntas fundamentales sobre los microbiomas de los distintos ecosistemas
  • El desarrollo de plataformas biotecnológicas para profundizar en el conocimiento de llos microbiomas en los distintos ecosistemas y apara reforzar el acceso a datos de microbiomas
  • La expansión de la fuerza de trabajo sobre el microbioma a través de la ciencia ciudadana, la participación del público, y las oportunidades educativas.

Ver también: https://www.whitehouse.gov/the-press-office/2016/05/12/fact-sheet-announcing-national-microbiome-initiative


Global Alliance for Genomics and Health

Global Alliance for Genomics and Health

 

 

 

Era7 es miembro de la Global Alliance que es una coalición internacional formada para facilitar el intercambio de información genómica y clínica, con la intención de impulsar los avances en las áreas de la medicina y la ciencia. Reúne a más de 220 instituciones líderes que trabajan en salud, investigación, ciencias biológicas e informática. 


MassBio

MassBio

 

 

 

 

Era7 es miembro de la asociación MassBio. El Massachusetts Biotechnology Council (MassBio) es una asociación de más de 650 empresas biotecnológicas, universidades, instituciones académicas y otras dedicadas al avance de la investigación más innovadora. MassBio es el principal defensor del primer cluster a nivel mundial de ciencias biológicas en el Bay State.


PACBIO

PacBio (http://www.pacb.com) es una de las tecnologías NGS de tercera generación más fascinantes en este momento. Sus secuencias son excepcionalmente largas (alrededor de 10.000 pares de bases) y de gran calidad una vez procesadas.

Colaboramos activamente con PacBio y tenemos servicios que PacBio ofrece como SMRT COMPATIBLE ANALYSIS PRODUCTS.

Actualmente tenemos un acuerdo de comarketing con PacBio y ofrecemos un servicio especializado de taxonomic profiling basado en el análisis del gen completo 16S con nuestro software MG7.


ASEBIO

ASEBIO

 

 

 

 

 

Era7 es socio de ASEBIO que es la Asociación Española de Bioempresas. ASEBIO agrupa a empresas, asociaciones, fundaciones, universidades, centros tecnológicos y de investigación que desarrollan sus actividades de manera directa o indirecta en relación con la biotecnología en España.

ASEBIO actúa desde 1999 como plataforma de encuentro y promoción de aquellas organizaciones interesadas en el desarrollo del escenario biotecnológico nacional. Para ello, colabora estrechamente con las administraciones regionales, nacionales y europeas, así como con todas aquellas organizaciones sociales interesadas en el uso de la biotecnología para la mejora de la calidad de vida, el medio ambiente y la generación de empleo cualificado.

 

Colaboradores de Investigación

Era7 Bioinformatics se basa en una cultura de colaboración

Trabajar en un área compleja, que cambia de forma muy rápida, precisa de una variada red de colaboraciones.

Siendo Open Source es una filosofía que impulsa la colaboración y el mejor resultado es casi siempre el fruto de este esfuerzo de colaboración.

Era7 Bioinformatics colabora con grupos de investigación e instituciones, proveedores de secuencias y otras compañías.

Puedes ver en nuestra web algunos de nuestros colaboradores de investigación:

 

Clientes de Era7

Siempre respetamos cuidadosamente la confidencialidad de nuestros clientes y de sus proyectos. 

Aquí puedes ver como se distribuyen geográficamente nuestros clientes que se concentran en Europa y en EEUU:

Product/Service

Era7 provides services in two areas: development of software for the processing of massive sequencing data, and obtention of data, analysis and obtention of solutions

In NGS, Era7 focuses in 16S metagenomics (microbiomes), bacterial genomics, bacterial comparative genomics and bacterial RNA-seq (transcriptomics) which provide massive data processed through Era7's main software: Bio4j. This platform is the base used to manage massive microbiological data, having demonstrated its capacity thanks to the support by Google in its development, making it a reference in precision medicine in microbiology. Era7 is developing a project through its platform for the analysis of microbiomes in hospitals and its integration in the patient's clinical history, which is accessible for the doctor. 

 

The integrated service offers the client: experimental design, sequencing, bioinformatic analysis, result interpretation and custom-made software to manage the obtained data. Era7's team starts on the experimental design and preparation of samples, to then find the most adequate sequencing provider and finally compute the data with its own massive sequencing software Bio4j. In the analysis it has a large pipeline creater directly from the team's research, and it thus interprets the obtaines results in a way that the client obtains a detailed report of the solutions to its research.  

 

 

Era7's bacterial specialization gives a clear diferentiation while also providing a large market.The number of potential applications for bacterial massive sequencing makes it a large growing market. 

The business model is the provision of complete NGS services in the field of bacteriology. These services go from the design of the project to the data analysis, including lab sequencing. Although Era7 has a small lab for sample management, sequencing services are outsourced to a number of suppliers. This model gives flexibility and adaptability to the market, since our sequencing and interpretation services are useful for any type of sequence regardless of the sequencing technology used. 

Era7's data analysis is very competitive and of high quality, based in propietary tools like BG7 and MG7 (for the annotation of bacterial genomes and 16S metagenomics analysis, respectively) with a later intervention of an expert in Bioinformatics and Microbiology. 

Era7 Bioinformatics has currently demonstrated that its business model works and that, due to all the R+D done in the company it is easily scalable

 

Market

Era7's clients come from a number of sectors and with an international perspective, given that, even though the company started in Granada, the company expanded to Massachussets, USA in 2012, the largest microbiome market in the world. Its massive sequencing services are orientated to biotech, pharmaceutical and food companies, research centers, universities and hospitals. 

Marketing & sales

Sales forecast for our integral services in Microbiology NGS: Microbiomes (16S), Genomics (PacBio de novo Genome, MiSeq de novo genome and RNA-seq) and Antibiotic Resistance and Virulence studies:

These sales would be obtained exclusively through the development of this business plan: they would be additional sales to the ones forecasted by Era7 without the execution of this particular business project. 

Roadmap

  1. Automatize some services which still required a lot of manual activity by Era7's experts to make them more scalable

  2. Incorporate to our bioinformatic platform Bio4j specific datasets for pathogenic bacteria and microbiomes to count with a specialized knowledge base in bacteria and a graph paradigm. Integrate in Bio4j every resource related to these aspects to take advantage of Bio4j in our bacterial genomics services. To make is short, develop the Microbio4j platform. 

  3. Design and develop a database of antibiotic resistance genes and virulence genes, which will help us provide advanced specialized services related to antibiotic resistance and bacterial pathogenicity. 

  4. Design and implement an innovative marketing strategy based on Era7's knowledge and communication skills. In regard to this, for example, we plan to launch a portal called "The Microbiome" (www.themicrobiome.com), aimed at offering valuable content on this topic, currently of great interest, to the community. 

Forecast

Descarga el Plan de Expansión de Era7 de este proyecto:

 

Ventas previstas de los servicios integrales de NGS en Microbiología : Microbiomas (16S), Genómica (Genoma de novo PacBio, genoma de novo MiSeq y RNA-seq) y Estudios de Resistencia a Antibióticos y Virulencia:

 

Investment details

This business plan has been designed to be developed in a year and a half, with three milestones:

           Milestone 1 , six months after starting the plan

  • -  New databases and bacterial/microbiome specific datasets modeled. Design of the software for the integraton of this data with Bio4j. 

  • -  Launch of “The Microbiome” portal

  • Milestone 2, up to twelve months after starting the plan 

  • -  New data and databases of antibiotic resistance and virulence genes already integrated with Bio4j. 

  • -  New interactive visualizations designed. 

  • -  Marketing and sales plan of the improved services designed. 

    Milestone 3 and end of the plan

  • -  New interactive visualizations integrated with the bioinformatic analysis pipeline. 

  • -  Marketing and sales plan implemented. 

What we aim to achieve:

  • -  More scalable services with lower costs, particularly for a large number of samples. 

  • -  More specialized services with rich and attractive reports, interactive visualizations and result management tools that take advantage of the data and ease its find-oriented interpretation.

  • -  Results and visualizations integrated with the electronic clinical history.

  • -  Offer new services for the analysis of:

    Microbiomes
    Antibiotic resistance
    Bacterial virulence and pathogenicity 

    These services will be reinforced by Bio4j's capacities, which will be enriched with specific resources for bacteria, antibiotic resistance and virulence. 

  • - Commercial expansion in the United States, where we already have a company and reference clients, who have positively received our services, particularly those related to antibiotic resistance in bacteria. 

    In short: significantly increase our sales

Exit details

La bioinformática es una necesidad no cubierta por la mayoría de las empresas farmacéuticas y relacionadas con biotecnología. Estos son sólo algunos ejemplos recientes de empresas bioinformáticas compradas por grandes empresas (farmacéuticas, de diagnóstico clínico, de secuenciación NGS):

  • CLC (empresa bioinformática) es comprada por QIAGEN (molecular diagnostics and pharma company)
  • Ingenuity (empresa bioinformática) es comprada por QIAGEN por 105 millones de dólares: